The role of inflammation in neurologic disease

Current Opinion in Critical Care

Volumn 6, Issue 2, 2000, Pages 98-109

  Morganti Kossmann, Maria Cristina ^a   Otto, Viviane I ^a   Stahel, Philip F ^a   Kossmann, Thomas ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR; CYTOKINE;

ANTIGEN EXPRESSION; BLOOD BRAIN BARRIER; BRAIN FUNCTION; CYTOKINE PRODUCTION; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NONHUMAN; PERIPHERAL CIRCULATION; REVIEW;

EID: 0033913736     PISSN: 10705295     EISSN: None     Source Type: Journal    
DOI: 10.1097/00075198-200004000-00005     Document Type: Review

References (133)

1. 1 Benveniste EN: The role of cytokines in multiple sclerosis/autoimmune encephalitis and other neurological disorders: In Human cytokines, their role in research and therapy. Edited by Agarwal B, Puri R. Boston: Blackwell Science, 1995:195-216.
2. 2 Lucchinetti CF, Brueck W, Rodriguez M, Lassmann H: Multiple sclerosis: lessons from neuropathology. Sem Neurology 1998, 18:337-349. This article offers an excellent description of the neuropathologic aspects peculiar to multiple sclerosis, with a particular enphasis on inflammation and production of tissue lesions.
3. 3 Raine CS: The immunology of the multiple sclerosis lesion. Ann Neurol 1994, 36:61-72.
4. 4 Hofman FM, Hinton DR, Johnson K, Merrill JE: Tumor necrosis factor identified in multiple sclerosis brain. J Exp Med 1989, 170:607-612.
5. 5 Selmaj KW, Raine CS: Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 1988, 23:339-346.
6. 6 Raine CS: The Norton lecture: a review of the oligodendrocyte in the multiple sclerosis lesion. J Neuroimmunol 1997, 77:135-152.
7. 7 Muir DA, Compston DA: Growth factor stimulation triggers apoptotic cell death in mature oligodendrocytes. J Neurosci Res 1996, 44:1-11.
8. 8 Gu C, Casaccia-Bonnefil P, Srinivasan A, Chao MV: Oligodendrocyte apoptosis mediated by caspase activation. J Neurosci 1999, 19:3043-3049.
9. 9 Ruddle NH, Bergman CM, McGrath KM, Lingenheld EG, Grunnet ML, Padula SJ, Clark RB: An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J Exp Med 1990, 172:1193-1200.
10. 10 Selmaj K, Papierz W, Glabinski A, Kohno T: Prevention of relapsing experimental autoimmune encephalomyelitis by soluble tumor necrosis factor receptor I. J Neuroimmunol 1995, 56:135-141.
11. 11 Campbell IL: Structural and functional impact of the transgenic expression of cytokines in the CNS. Ann N Y Acad Sci 1998, 840:83-96.
12. 12 Probert L, Akassoglou K, Pasparakis M, Kontogeorgos G, Kollias G: Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor-α. Proc Natl Acad Sci USA 1995, 92:11294-11298.
13. 13 Ruddle NH: Tumor necrosis factor (TNF-α) and lymphotoxin (TNF-β). Curr Opin Immunol 1992, 4:327-332.
14. 14 Bazzoni F, Beutler B: The tumor necrosis factor ligand and receptor families. N Engl J Med 1996, 334:1717-1725.
15. 15 Frei K, Eugster HP, Bopst M, Constantinescu CS, Lavi E, Fontana A: Tumor necrosis factor-α and lymphotoxin-α are not required for induction of acute experimental autoimmune encephalomyelitis. J Exp Med 1997, 12:2177-2182.
16. 16 Eugster HP, Frei K, Bachmann R, Bluethmann H, Lassmann H, Fontana A: Severity of symptoms and demyelination in MOG-induced EAE depends on TNFR1. Eur J Immunol 1999, 29:626-632.
17. 17 Liu J, Marino MW, Wong G, Grail D, Dunn A, Bettadapura J, Slavin AJ, Old L, Bernard CCA: TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nature Med 1998, 4:78-83.
18. 18 Riminton DS, Körner H, Strickland DH, Lemckert FA, Pollard JD, Sedgwick JD: Challenging cytokine redundancy: inflammatory cell movement and clinical course of experimental autoimmune encephalomyelitis are normal in lymphotoxin-deficient, but not tumor necorsis factor-deficient, mice. J Exp Med 1998, 187:1517-1528.
19. 19 Eugster HP, Frei K, Kopf M, Lassmann H, Fontana A: IL-6-deficient mice resist myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. Eur J Immunol 1998, 28:2178-2187.
20. 20 Dopp JM, Breneman SM, Olschowka JA: Expression of ICAM-1, VCAM-1, L-selectin and leukosialin in the mouse central nervous system during the induction and remission stages of experimental allergic encephalomyelitis. J Neuroimmunol 1994, 54:129-144.
21. 21 Lee SJ, Benveniste EN: Adhesion molecule expression and regulation on cells of the central nervous system. J Neuroimmunol 1999, 98:77-88. This paper reports experimental evidence on the role of adhesion molecules in MS/EAE, predominantly from in vitro and animal studies.
22. 22 Rudick RA, Ransohoff RM, Peppler R, van der Brug-Mendendorp S, Lehmann P, Alam J: Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis. Ann Neurol 1996, 40:618-627.
23. 23 Kennedy MK, Torrance DS, Picha KS, Mohler KM: Analysis of cytokine mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery. J Immunol 1992, 149:2496-2505.
24. 24 Rott O, Fleischer B, Cash E: Interleukin-10 prevents experimental allergic encephalomyelitis in rats. Eur J Immunol 1994, 24:1434-1440.
25. 25 Barger S: Tumor necrosis factor, the good the bad and the umbra. In Neuroprotective signal transduction. Edited by Mattson MP. Totowa, NJ: Humana Press 1998:163-183. The dual role of TNF and the secondary pathways mediated by its receptors are described in this review article.
26. 26 Yong VW, Chabot S, Stuve O, Williams G: Interferon beta in the treatment of multiple sclerosis. Mechanisms of action. Neurology 1998, 51:682-689.
27. 27 Baggiolini M, Dewald B, Moser B: Human chemokines: an update. Annu Rev Immunol 1997, 15:675-705.
28. 28 Glabinski AR, Ransohoff RM: Chemokines and chemokine receptors in CNS pathology. J Neurovirology 1999, 5:3-12. This review reports the expression and function of chemokines and chemokine receptors in neuropathologies such as MS/EAE and CNS inury. It also discusses the effect of their overexpression in transgenic mice and regulatory mechanisms by cultured cells.
29. 29 Glabinski AR, Tani M, Tuohy VK, Tuthill RJ, Ransohoff RM: Central nervous system chemokine gene expression follows leukocyte entry in acute murine experimental autoimmune encephalomyelitis. Brain Behav Immun 1996, 9:315-330.
30. 30 Godiska R, Chantry D, Dietsch G, Gray P: Chemokine expression in murine experimental autoimmune encephalomyelitis. J Neuroimmunol 1995, 58:167-176.
31. 31 Glabinski A, Tani M, Strieter R, Tuohy V, Ransohoff R: Synchronous synthesis of α-and β-chemokines by cells of diverse lineage in the central nervous system of mice with relapses of experimental autoimmune encephalomyelitis. Am J Pathol 1997, 150:617-630.
32. 32 Karpus WJ, Kennedy KJ, Lucchinetti CF, Bruck W, Rodriguez M, Lassmann H: MIP-1α and MCP-1 differentially regulate acute and relapsing autoimmune encephalomyelitis as well as Th1/Th2 lymphocyte differentiation. J Leukoc Biol 1997, 62:681-687.
33. 33 Van der Voorn P, Tekstra J, Beelen RHJ, Tensen CP, Van der Valk P, De Groot CJA: Expression of MCP-1 by reactive astrocytes in demyelinating multiple sclerosis lesions. Am J Pathol 1999, 154:45-51.
34. 34 Miyagishi R, Kikuchi S, Fukazawa T, Tashiro K: Macrophage inflammatory protein-1α in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological diseases. J Neurol Sci 1995, 129:223-227.
35. 35 Tani M, Fuentes ME, Peterson JW, Trapp BD, Durham SK, Loy JK, Bravo R, Ransohoff RM: Neutrophil infiltration, glial reaction and neurological disease in transgenic mice expressing the chemokine N51/KC in oligodendrocytes. J Clin Invest 1996, 98:529-539.
36. 36 Kelvin DJ, Michiel DF, Johnston JA, Lloyd AR, Sprenger H, Oppenheim JJ, Wang JM: Chemokines and serpentines: the molecular biology of chemokine receptors. J Leukoc Biol 1993, 54:604-612.
37. 37 Premack BA, Schall TJ: Chemokine receptors: gateways to inflammation and infection. Nature Med 1996, 2:1174-1178.
38. 38 Jiang Y, Salafranca MN, Adhikari S, Xia Y, Feng L, Sonntag MK, deFiebre CM, Pennell NA, Streit WJ, Harrison JK: Chemokine receptor expression in cultured glia and rat experimental allergic encephalomyelitis. J Neuroimmunol 1998, 86:1-12.
39. 39 Xia M, Qin S, Wu L, Mackay CR, Hyman BT: Immunohistochemical study of the β-chemokine receptors CCR3 and CCR5 and their ligands in normal and Alzheimer's disease brains. Am J Pathol 1998, 153:31-37.
40. 40 Zou YR, Kottmann AH, Kuroda M, Taniuchi I, Littman DR: Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 1998, 393:524-525.
41. 41 Westmoreland SV, Rottman JB, Williams KC, Lackner AA, Sasseville VG: Chemokine receptor expression on resident and inflammatory cells in the brain of macaques with simian immunodeficiency virus encephalitis. Am J Pathol 1998, 152:659-665.
42. 42 Lavi E, Strizki JM, Ulrich AM, Zhang W, Fu L, Wang Q, O'Connor M, Hoxie JA, Gonzalez-Scarano F: CXCR-4 (Fusin), a co-receptor for the type 1 human immunodeficiency virus (HIV-1), is expressed in the human brain in a variety of cell types, including microglia and neurons. Am J Pathol 1997, 151:1035-1042.
43. 43 Horuk R, Martin AW, Wang Z, Schweizer L, Gerassimides A, Guo H, Lu Z, Hesselgesser J, Perez HD, Kim J, Parker J, Hadley TJ, Peiper SC: Expression of chemokines receptors by subsets of neurons in the central nervous system. J Immunol 1997, 158:2882-2890.
44. 44 Xia M, Qin S, McNamara M, Mackay CR, Hyman BT: Interleukin-8 receptor B immunoreactivity in brain and neuritic plaques of Alzheimer's disease. Am J Pathol 1997, 150:1267-1274.
45. 45 Barnum SR: Inhibition of complement as a therapeutic approach in inflammatory central nervous system disease. Mol Med 1999, 5:569-582. The new aspects and consequences of complement activation in CNS diseases and their potential application in therapy are discussed in this excellent review.
46. 46 Nataf S, Stahel PF, Davoust N, Barnum SR: Complement anaphylatoxin receptors on neurons: new tricks for old receptors? Trends Neurosci 1999, 22:397-402. This article reports the functions and neuronal expression of the chemotactic and anaphylactic complement peptides C5a and C3a and their receptors in normal brain, meningitis, injury and MS/EAE.
47. 47 Morgan BP, Gasque P, Singhrao S, Piddlesden SJ: The role of complement in disorders of the nervous system. Immunopharmacology 1997, 38:43-50.
48. 48 Nataf S, Davoust N, Ames RS, Barnum SR: Human T cells express the C5a receptor and are chemoattracted to C5a. J Immunol 1999, 162:4018-4023.
49. 49 Nataf S, Davoust N, Barnum SR: Kinetics of anaphylatoxin C5a receptor during experimental allergic encephalomyelitis. J Neuroimmunol 1998, 91:147-155.
50. 50 Gasque P, Singhrao SK, Neal JW: The receptor for complement anaphylatoxin C3a is expressed by myeloid cells and nonmyeloid cells in inflamed human central nervous system: analysis in multiple sclerosis and bacterial meningitis. J Immunol 1998, 160:3543-3554.
51. 51 Davoust N, Jones J, Stahel PF, Ames RS, Barnum SR: Receptor for the C3a anaphylatoxin is expressed by neurons and glial cells. Glia 1999, 26:201-211.
52. 52 Bell JE: The neuropathology of adult HIV infection. Rev Neurol (Paris) 1998, 154:816-829. The neuropathologic aspects of HIV infection of the brain and spinal cord are described in a detailed fashion up to cellular and molecular levels. Included are also the neuropathologic complications of opportunistic infections and neoplasms after viral spread within the CNS.
53. 53 Nottet HS, Persidsky Y, Sasseville VG, Nukuna AN, Bock P, Zhai QH, Sharer LR, McComb RD, Swindells S, Soderland C, Gendelman HE: Mechanisms for transendothelial migration of HIV-1-infected monocytes into brain. J Immunol 1996, 156:1284-1295.
54. 54 Takahashi K, Wesselingh SL, Griffin DE, McArthur JC, Johnson RT, Glass JD: Localization of HIV-1 using polymerase chain reaction/in situ hybridization and immunohistochemistry. Ann Neurol 1996, 39:705-711.
55. 55 Wesselingh SL, Takahashi K, Glass JD, McArthur JC, Griffin JW, Griffin DE: Cellular localization of tumor necrosis factor mRNA in neurological tissue from HIV-infected patients by combined reverse transcriptase/polymerase chain reaction in situ hybridization and immunohistochemistry. J Neuroimmunol 1997, 74:1-8.
56. 56 Griffin DE: Cytokines in the brain during viral infection: clues to HlV-associated dementia. J Clin Invest 1997, 100:2948-2951.
57. 57 Tyor WR, Glass JD, Griffin JW, Becker PS, McArthur JC, Bezman L, Griffin DE: Cytokine expression in the brain during AIDS. Ann Neurol 1992, 31:349-360.
58. 58 Gallo P, Frei K, Rordorf C, Lazdins J, Tavolato B, Fontana A: Human immunodeficiency virus type-1 (HIV-1) infection in the central nervous system: an evaluation of cytokines in cerebrospinal fluid. J Neuroimmunol 1989, 23:109-116.
59. 59 Morganti-Kossmann MC, Kossmann T, Wahl SM: Cytokines and neuropathology. Trends Pharmacol Sci 1992, 13:286-291.
60. 60 Rappaport J, Joseph J, Croul S, Alexander G, Del Valle L, Amini S, Khalili-K: Molecular pathway involved in HIV-induced CNS pathology: role of viral regulatory protein Tat. J Leukoc Biol 1999, 65:458-465.
61. 61 Kootstra NA, van't-Wout A, Huisman HG, Miedema F, Schuitemaker H: Interference of interleukin-10 with human immunodeficiency virus type 1 replication in primary monocyte-derived macrophages. J Virol 1994, 68:6967-6975.
62. 62 Wahl SM, Allen JB, McCartney-Francis N, Morganti-Kossmann MC, Kossmann T, Ellingsworth L, Mai UE, Mergenhagen SE, Orenstein JM: Macrophage-and astrocyte-derived transforming growth factor beta as a mediator of central nervous system dysfunction in acquired immune deficiency syndrome. J Exp Med 1991, 173:981-991.
63. 63 Da Cuhna A, Jackson RW, Vitkovic L: HIV-1 nonspecifically stimulates production of transforming growth factor-beta1 transfer in primary astrocytes. J Neuroimmunol 1995, 60:125-133.
64. 64 He J, Chen Y, Farzan M, Choe H, Ohagen A, Gartner S, Busciglio J, Yang X, Hofmann W, Newman W, Mackay CR, Sodroski J, Gabuzda D: CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia. Nature 1997, 385:645-649.
65. 65 Tanabe S. Heesen M, Yoshizawa I, Berman MA, Luo Y, Bleul CC, Springer TA, Okuda K, Gerard N, Dorf ME: Functional expression of the CXC-chemokine receptor-4/fusin on mouse microglial cells and astrocytes. J Immunol 1997, 159:905-911.
66. 66 Neumann M, Felber BK, Kleinschmidt A, Froese B, Erfle V, Pavlakis GN, Brack-Werner R: Restriction of human immunodeficiency virus type 1 production in a human astrocytoma cell line is associated with a cellular block in Rev function. J Virol 1995, 69:2159-2167.
67. 67 Lavi E, Kolson DL, Ulrich AM, Fu L, Gonzàlez-Scarano F: Chemokine receptors in the human brain and their relationship to HIV infection. J Neurovirol 1998, 4:301-311. Recent findings that involve chemokine/chemokine receptors in cellular HIV entry are reviewed in this article. These receptors may play a fundamental role in infection of cells within the CNS that do not express CD4, and thus in the pathogenesis of HIV-encephalopathy.
68. 68 Kelder W, McArthur JC, Nance-Sproson T, McClernon D, Griffin DE: β-chemokines MCP-1 and RANTES are selectively increased in cerebrospinal fluid of patients with human immunodeficiency virus-associated dementia. Ann Neurol 1998, 44:831-835.
69. 69 Morganti-Kossmann MC, Kossmann T: The immunology of brain injury. In: Immune responses in the nervous system. Edited by Rothwell NJ. Oxford: Bios Scientific Publishers, 1995:159-187.
70. 70 McIntosh TK, Smith DH, Meaney DF, Kotapka MJ, Gennarelli TA, Graham DI: Neuropathological sequelae of traumatic brain injury: relationship to neurochemical and biomechanical mechanisms. Lab Invest 1996, 74:315-342.
71. 71 Povlishock JT: An overview of brain injury models. In: Narayan RK, Wilberger JE, Povlishock JT, eds. Neurotrauma. New York: McGraw-Hill, 1995:1325-1336.
72. 72 Quattrocchi KB, Issel BW, Miller CH, Frank EH, Wagner FC: Impairment of helper T-cell function following severe head injury. J Neurotrauma 1992, 9:1-9.
73. 73 Goodman JC, Robertson CS, Grossman RG, Narayan RK: Elevation of tumor necrosis factor in head injury. J Neuroimmunol 1990, 30:212-217.
74. 74 McClain CJ, Cohen D, Ott L, Dinarello CA, Young B: Ventricular fluid interleukin-1 activity in patients with head injury. J Lab Clin Med 1987, 110:48-54.
75. 75 McClain C, Cohen D, Phillips R, Ott L, Young B: Increased plasma and ventricular fluid interleukin-6 levels in patients with head injury. J Lab Clin Med 1991, 118:225-231.
76. 76 Kossmann T, Hans VHJ, Imhof HG, Stocker R, Grob P, Trentz O, Morganti-Kossmann MC: Intrathecal and serum interleukin-6 and the acute-phase response in patients with severe traumatic brain injuries. Shock 1995, 5:311-317.
77. 77 Kossmann T, Stahel PF, Lenzlinger PM, Redl H, Dubs RW, Trentz O, Schlag G, Morganti-Kossmann MC: Interleukin-8 released into the cerebrospinal fluid after brain injury is associated with blood-brain barrier dysfunction and nerve growth factor production. J Cereb Blood Flow Metab 1997, 17:280-289.
78. 78 Morganti-Kossmann MC, Lenzlinger PM, Hans V, Stahel P, Csuka E. Ammann E, Stocker R, Trentz O, Kossmann T: Production of cytokines following brain injury: beneficial and deleterious for the damaged tissue. Mol Psychiatry 1997, 2:133-136.
79. 79 Morganti-Kossmann MC, Hans VHJ, Lenzlinger PM, Dubs R, Ludwig E, Trentz O, Kossmann T: TGF-β is elevated in the CSF of patients with severe traumatic brain injuries and parallels blood-brain barrier function. J Neurotrauma 1999, 16:617-628.
80. 80 Hans V, Kossmann T, Joller H, Otto V, Morganti-Kossmann MC: Interleukin-6 and its soluble receptor in serum and cerebrospinal fluid after cerebral trauma. Neuroreport 1999, 10:409-412.
81. 81 Csuka E, Morganti-Kossmann MC, Lenzlinger PM, Joller H, Trentz O, Kossmann T: IL-10 levels in cerebrospinal fluid and serum of patients with severe traumatic brain injury: relationship to IL-6, TNF-α, TGF-β1 and blood-brain barrier dysfunction. J Neuroimmunol 1999 101:211-221.
82. 82 Ramilo O, Saez Llorens X, Mertsola J, Jafari H, Olsen KD, Hansen EJ, Yoshinaga M, Ohkawara S, Nariuki H, McCracken GH: Tumor necrosis factor-α/cachetin and interleukin-1β initiate meningeal inflammation. J Exp Med 1990, 172:3012-3017.
83. 83 Banks WA, Kastin AJ, Broadwell RD: Passage of cytokines across the blood brain barrier. Neuroimmunomodulation 1995, 2:241-248.
84. 84 De Vries HE, Blom-Roosemalen MC, van Oosten M, deBoer AG, van Berkel TJ, Breimer DD, Kuiper J: The influence of cytokines on the integrity of the blood-brain barrier in vitro. J Neuroimmunol 1996, 64:37-43.
85. 85 Maruo N, Morita I, Shirao M, Murota S: IL-6 increases endothelial permeability in vitro. Endocrinology 1992, 131:710-714.
86. 86 Giulian D, Chen J, Ingeman JE, George JK, Noponen M: The role of mononuclear phagocytes in wound heating after traumatic injury to adult mammalian brain. J Neurosci 1989, 9:4416-4429.
87. 87 Woodroofe MN, Sarna GS, Wadhwa M, Hayes GM, Loughlin AJ, Tinker A, Cuzner ML: Detection of interleukin-1 and interleukin-6 in adult rat brain, following mechanical injury, by in vivo microdialysis: evidence of a role for microglia in cytokine production. J Neuroimmunol 1991, 33:227-236.
88. 88 Taupin V, Toulmond S, Serrano A, Benavides J, Zavala F: Increase in IL-6, IL-1 and TNF levels in rat brain following traumatic lesion. J Neuroimmunol 1993, 42:177-186.
89. 89 Shohami E, Novikov M, Bass R, Yamin A, Gallily R: Closed head injury triggers early production of TNFα and IL-6 by brain tissue. J Cereb Blood Flow Metab 1994, 14:615-619.
90. 90 Fan L, Young PR, Barone FC, Feuerstein GZ, Smith DH, McIntosh TK: Experimental brain injury induces expression of interleukin-1β mRNA in the rat brain. Mol Brain Res 1995, 30:125-130.
91. 91 Fan L, Young PR, Barone FC, Feuerstein GZ, Smith DH, McIntosh TK: Experimental brain injury induces differential expression of tumor necrosis factor-α mRNA in the CNS. Mol Brain Res 1996, 36:287-291.
92. 92 Shohami E: Dual role of tumor necrosis factor alpha in brain injury. Cytokine Growth Factors Rev 1999, 10:119-130. The role of TNF in brain injury due to ischemia and trauma is discussed in this paper. It reports the numerous attempts to block TNF activities as well as the use of TNF knockout mice in experimental TBI.
93. 93 McIntosh TK, Juhler M, Wieloch T: Novel pharmacologic strategies in the treatment of experimental traumatic brain injury: 1998. J Neurotrauma 1998, 15:731-769. Both experimental as well as clinical pharmacologic attempts to improve outcome after brain injury are reported in this article in the broadest manner.
94. 94 Knoblach SM, Fan L, Faden AI: Early neuronal expression of tumor necrosis factor-alpha after experimental brain injury contributes to neurological impairment. J Neuroimmunol 1999, 95:115-125.
95. 95 Scherbel U, Raghupathi R, Nakamura M, Saatman KE, Trojanowski JQ, Neugebauer ED, Marino MW, McIntosh TK: Differential acute and cronic responses of tumor necrosis factor-deficient mice to experimental brain injury. Proc Natl Acad Sci USA 1999, 96:8721-8726.
96. 96 Stahel PF, Shohami E, Younis FM, Kariya K, Otto VI, Lenzlinger PM , Grosjean MB, Eugster HP, Trentz O, Kossmann T, Morganti-Kossmann MC: Experimental closed head injury: analysis of neurological outcome, blood-brain barrier dysfunction, intracranial neutrophil infiltration and neuronal cell death in mice deficient in genes for pro-inflammatory cytokines. J Cereb Blood Flow Metab 2000 (in press).
97. 97 Penkowa M, Moos T, Carrasco J, Hadberg H, Molinero A, Bluethmann H, Hidalgo J: Strongly compromised inflammatory response to brain injury in interleukin-6-deficient mice. Glia 1999, 25:343-357.
98. 98 Toulmond S, Rothwell NJ: Interleukin-1 receptor antagonist inhibits neuronal damage caused by fluid percussion injury in the rat. Brain Res 1995, 671:261-266.
99. 99 DeKosky ST, Styren SD, O'Malley ME, Goss JR, Kochanek P, Marion D, Evans CH, Robbins PD: Interleukin-1 receptor antagonist suppresses neurotrophin response in injured rat brain. Ann Neurol 1996, 39:123-127.
100. 100 Balasingam V, Yong VW: Attenuation of astroglial reactivity by interleukin-10. J Neurosci 1996, 16:2945-2955.
101. 101 Kossmann T, Hans V, Imhof HG, Trentz O, Morganti-Kossmann MC: Interleukin-6 released into human cerebrospinal fluid following traumatic brain injury may trigger nerve growth factor production in astrocytes. Brain Res 1996, 713:143-152.
102. 102 Toulmond S, Vige X, Fage D, Benavides J: Local infusion of interleukin-6 attenuates the neurotoxic effects of NMDA on rat striatal cholinergic neurons. Neurosci Lett 1992, 144:49-52.
103. 103 Marmarou A, Foda MAA, van den Brink W, Campbell C, Kita H, Demetriadou K: A new model of diffuse brain injury in rats. Part I: Pathophysiology and biomechanics. J Neurosurg 1994, 80:291-300.
104. 104 Hans V, Kossmann T, Lenzlinger P, Probstmeier R, Imhof H-G, Trentz O, Morganti-Kossmann MC: Experimental axonal injury triggers interleukin-6 mRNA, protein synthesis and release into cerebrospinal fluid. J Cereb Blood Flow Metab 1999, 19:184-194.
105. 105 Rimaniol AC, Lekieffre D, Serrano A, Masson A, Benavides J, Zavala F: Biphasic transforming growth factor-beta production flanking the proinflammatory cytokine response in cerebral trauma. Neuroreport 1995, 7:133-136.
106. 106 Knoblach SM, Faden AI: Interleukin-10 improves outcome and alters proinflammatory cytokine expression after experimental traumatic brain injury. Exp Neurol 1998, 153:143-151.
107. 107 Aihara N, Hall JJ, Pitts LH, Fukuda K, Noble L: Altered immunoexpression of microglia and macrophages after mild head injury. J Neurotrauma 1995, 12:53-63.
108. 108 Soares HD, Hicks RR, Smith DH, McIntosh TK: Inflammatory leukocyte recruitment and diffuse neuronal degeneration are separate pathological processes resulting from traumatic brain injury. J Neurosci 1995, 15:8223-8233.
109. 109 Carlos TM, Clark RSB, Franicola-Higgins D, Schiding JK, Kochanek PM: Expression of endothelial adhesion molecules after traumatic brain injury in rats. J Neurotrauma 1995, 12:458-468.
110. 110 McKeating EG, Andrews PJD: Cytokines and adhesion molecules in acute brain injury. Br J Anesth 1998, 80:77-84. This is a short but comprehensive review article on the role of cytokines and adhesion molecules in traumatic brain injury.
111. 111 Connolly ES, Winfree CJ, Springer TA, Naka Y, Liao H, Yan SD, Stern DM, Solomon RA, Gutierrez-Ramos JC, Pinsky DJ: Cerebral protection in homozygous null ICAM-1 mice after middle cerebral artery occlusion. Role of neutrophil adhesion in the pathogenesis of stroke. J Clin Invest 1996, 97:209-216.
112. 112 Whalen MJ, Carlos TM, Dixon CE, Schiding JK, Clark RSB, Baum E, Yan HQ, Marion DW, Kochaneck PM: Effect of traumatic brain injury in mice deficient in intercellular cell adhesion molecule-1: assessment of histopathologic and functional outcome. J Neurotrauma 1999, 16:299-309.
113. 113 Lo WD, Chen R, Boue DR, Stokes BT: Effect of neutrophil depletion in acute cerebritis. Brain Res 1998, 802:175-183.
114. 114 Pleines UE, Stover JF, Kossmann T, Trentz O, Morganti-Kossmann MC: Soluble ICAM-1 coincides with the extent of cerebral damage in patients with severe traumatic brain injury. J Neurotrauma 1998, 15:399-409.
115. 115 Ransohoff RM, Tani M: Do chemokines mediate leukocyte recruitment in post-traumatic CNS Inflammation? Trends Neurosci 1998, 21:154-159. This is a review of the recent data on chemokine function in autoimmune and posttraumatic inflammation with regard to cerebral accumulation of leukocytes.
116. 116 Asensio VC, Campbell IL: Chemokines in the CNS: plurifunctional mediators in diverse states. Trends Neurosci 1999, 22:504-512. In this article not only the function of chemokine and their receptors is reviewed in pathology but also during the development and in normal CNS function.
117. 117 Glabinski AR, Balasingam V, Tani M, Kunkel SL, Strieter RM, Yong VW, Ransohoff RM: Chemokine monocyte chemoattractant protein-1 is expressed by astrocytes after mechanical injury to the brain. J Immunol 1996, 156:4363-4368.
118. 118 Hausmann EHS, Berman NEJ, Wang YY, Meara JB, Wood GW, Klein RM: Selective chemokine mRNA expression following brain injury. Brain Res 1998, 788:49-59.
119. 119 Ghirnikar RS, Lee YL, Eng LF: Inflammation in traumatic brain injury: role of cytokines and chemokines. Neurochemical Research 1998, 23:329-340.
120. 120 Peterson PK, Hu SX, Salakl-Johnson J, Molitor TW, Chao CC: Differential production of and migratory response to β chemokines by human microglia and astrocytes. J Infect Dis 1997, 175:478-481.
121. 121 Stahel PF, Morganti-Kossmann MC, Kossmann T: The role of complement system in traumatic brain injury. Brain Res Rev 1998, 27:243-256.
122. 122 Becker P, Zeigler S, Rother U, Lutz H, Osswald PM: Complement activation following traumatic brain injury. Anästhesist 1987, 36:301-306.
123. 123 Kossmann T, Stahel PF, Morganti-Kossmann MC, Jones JL, Barnum SR: Elevated levels of the complement components C3 and factor B in ventricular cerebrospinal fluid of patients with traumatic brain injury. J Neuroimmunol 1997, 73:63-69.
124. 124 Törnqvist E, Liu L, Aldskogius H, von Holt H, Svensson M: Complement and clusterin in the injured nervous system. Neurobiol Aging 1996, 17:695-705.
125. 125 Bellander BM, von Holst H, Fredman P, Svennson M: Activation of the complement cascade and increase of clusterin in the brain following a cortical confusion in the adult rat. J Neurosurg 1996, 85:468-475.
126. 126 Kaczorowski SL, Schiding JK, Toth CA, Kochanek PM: Effect of soluble complement receptor-1 on neutrophil accumulation after traumatic brain injury in rats. J Cereb Blood Flow Metab 1995, 15:860-864.
127. 127 Stahel PF, Kossmann T, Morganti-Kossmann MC, Hans VHJ, Barnum SR: Experimental diffuse axonal injury induces enhanced neuronal C5a receptor mRNA expression in rats. Mol Brain Res 1997, 150:205-212.
128. 128 Farkas I, Baranyi L, Liposits ZS, Yamamoto T, Okada H: Complement C5a anaphylatoxin fragment causes apoptosis in TGW neuroblastoma cells. Neuroscience 1998, 86:903-911.
129. 129 Rink A, Fung KM, Trojanowski JQ, Lee VMY, Neugebauer E, McIntosh TK: Evidence of apoptotic cell death after experimental traumatic brain injury in the rat. Am J Pathol 1995, 47:1575-1583.
130. 130 Sharief MK, Phil M, Hentges R: Association between tumor necrosis factor-α and disease progression in patients with multiple sclerosis. N Engl J Med 1991, 325:467-472.
131. 131 Shohami E, Bass R, Wallach D, Yamin A, Gallily R: Inhibition of tumor necrosis factor alpha (TNF-α) activity in rat brain is associated with cerebroprotection after closed head injury. J Cereb Blood Flow Metab 1996, 16:378-384.
132. 132 Shohami E, Gallily R, Mechoulam R, Bass R, Ben Hur T: Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-alpha inhibitor and an effective neuroprotectant. J Neuroimmunol 1997, 72:169-177.
133. 133 Ross SA, Halliday MI, Cambell GC, Byrnes DP, Rowlands BJ: Br J Neurosurg 1994, 8:419-425.